Advanced Materials · 2023 · 41 citations · 35 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer VaccinesCombination ImmunotherapyPhotodynamic TherapyPhotothermal TherapyTumor-associated AntigensAntigen Presenting CellsCancer ImmunostimulationCancer Immunotherapy NanoparticlesPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 TargetingTumor Antigen-based ImmunotherapyTumor-associated Antigen Vaccines
Abstract The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti‐tumor immunity. In the present study, a nanoplatform (Fe 3 O 4 @IR820@CpG)‐based immunotherapy strategy that targets the multiple key steps in cancer‐immunity cycle is developed: 1) promotes the release of tumor‐derived proteins (TDPs), including tumor‐associated antigens and pro‐immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll‐like receptor 9 agonist) to antigen‐presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor‐killing ability of T cells by combining with anti‐programmed death ligand 1 antibody ( α ‐PD‐L1), which collectively advances the outstanding of the anti‐tumor effects on colorectal, liver and breast cancers. The broad‐spectrum anti‐tumor activity of Fe 3 O 4 @IR820@CpG with α ‐PD‐L1 demonstrates that optimally manipulating anti‐cancer immunity not singly but as a group provides promising clinical strategies.
35
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Yuanzeng Min, Kyle C. Roche, Shaomin Tian et al. · Nature Nanotechnology · 2017 · 689 citations
Life Sciences, Immunology, Oncology +16
Combining Nanomedicine and Immunotherapy
Yang Shi, Twan Lammers · Accounts of Chemical Research · 2019 · 456 citations · Full text
Life Sciences, Immunology, Oncology +14